**Appendix Table D10. Reduction in frequency of migraine attack by at least 50% from baseline with topiramate vs. placebo in children (pooled with random effects results from randomized controlled clinical trials)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference Dose of drug** | **Events/**  **randomized**  **active** | **Events/**  **randomized**  **control** | **Relative risk**  **(95% CI)** | **Weight** | **Absolute risk difference**  **(95% CI)** | **Weight** | **Risk of bias** |
| **100-200mg/day** |  |  |  |  |  |  |  |
| Winner, 20058 50 mg/day at week 3, titrated to a max dose of 200 mg/day (2-3kg mg/kg/day) | 61/112 | 23/50 | 1.18  (0.84 to 1.67) | 39.71 | 0.09 (-0.08 to 0 .25) | 37.29 | Medium |
| Lewis, 20097 25mg/day initially and then gradually increased to 100mg/day, dosed twice daily \* | 29/35 | 15/33 | 1.82  (1.22 to 2.73) | 34.41 | 0.37 (0.16 to 0.59) | 32.65 | Low |
| Pooled |  |  | 1.45  (0.95 to 2.21) | 74.12 | 0.22 (-0.06 to 0 .51) | 69.94 |  |
| **50 mg/day** |  |  |  |  |  |  |  |
| Lewis, 20097 25mg/day initially and then gradually increased to 50mg/day, dosed twice daily at the investigator’s discretion | 16/35 | 15/33 | 1.01  (0.60 to 1.69) | 25.88 | 0.00 (-0.23 to 0 .24) | 30.06 | Low |
| Pooled overall |  |  | 1.32  (0.94 to 1.84) | 100 | 0.15 (-0.06 to 0.37) | 100 |  |
| Heterogeneity statistic |  |  | P value = 0.142  I squared = 48.7% |  | P value = 0.04  I squared = 68.8% |  |  |

**\*-** at the investigator’s discretion the dose was increased to the maximal dose tolerated by the subjects, 91% achieved the target daily dose during the double-blind treatment phase, the daily dose used during the entire double-blind treatment phase (titration and maintenance) was 73.6 ±18.7 mg/day